UroGen Pharma (URGN) Other Non-Current Assets (2016 - 2026)

UroGen Pharma (URGN) has reported Other Non-Current Assets for 11 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Assets rose 1919.68% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 1919.68% YoY) and the FY2025 annual result came in at $5.2 million, up 776.23% from the prior year.
• Other Non-Current Assets grew to $7.5 million in Q1 2026 per URGN's latest filing, from $5.2 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for URGN reached as high as $7.5 million in Q1 2026 and fell as low as $370000.0 in Q3 2024.
• A 5-year average of $2.5 million and a median of $2.0 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 2281.82% — and 2024, when it slumped 81.95%.
• Year by year, Other Non-Current Assets stood at $2.7 million in 2022, then retreated by 25.62% to $2.0 million in 2023, then tumbled by 71.1% to $589000.0 in 2024, then soared by 776.23% to $5.2 million in 2025, then surged by 45.19% to $7.5 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $7.5 million, $5.2 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.